The AVL9 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the human hepatic adenocarcinoma cell line SK-HEP-1, carrying a targeted disruption of the AVL9 gene. This loss-of-function model enables detailed investigation of AVL9-mediated retrograde trafficking from late endosomes to the trans-Golgi network (TGN). By eliminating functional AVL9 expression within a heterogeneous knockout pool, researchers can study the cellular consequences of disrupted GARP- and EARP-dependent tethering complexes in a liver cancer context without clonal artifacts.
SK-HEP-1 is a well-characterized liver adenocarcinoma cell line originally established from the ascitic fluid of a 52-year-old male patient. These cells are notable for their endothelial-like properties and are widely employed in hepatic cancer research, including studies of tumorigenesis, metastasis, and angiogenesis. Their unique phenotypic duality makes them a valuable platform for interrogating the interplay between endosomal trafficking and oncogenic processes in hepatocellular carcinoma.
AVL9 functions as a critical component of the GARP and EARP tethering complexes, which mediate the docking of late endosome-derived vesicles at the TGN. It facilitates SNARE-mediated fusion through interactions with VAMP4, STX6, STX16, and VTI1A, enabling the retrieval of TGN-resident proteins such as TGN46 and the cation-independent mannose-6-phosphate receptor (CI-M6PR). Upstream, AVL9 is regulated by the mTORC1 pathway and the transcription factor TFEB, while it physically assembles with VPS51, VPS52, VPS53, VPS54, and VPS50 to maintain retrograde transport and Golgi integrity.
In the context of SK-HEP-1 cells, AVL9 knockout disrupts retrograde trafficking, leading to mislocalization of TGN enzymes and impaired receptor recycling. This perturbation offers a physiologically relevant model for linking Golgi dysfunction to hepatocellular carcinoma progression. Defects in endosome-to-TGN transport have been associated with altered cell migration, invasion, and lysosomal degradation, making this knockout tool particularly suited for dissecting how trafficking pathways influence malignant phenotypes in liver cancer.
Typical applications include immunofluorescence localization of TGN46 and CI-M6PR to assess Golgi morphology, Western blotting for GARP subunits, retrograde transport assays using CD8a-CIMPR chimeras, and transwell invasion or migration studies. The cells are also amenable to transcriptomic profiling via RNA-seq and functional assays addressing autophagy and apoptosis. For additional technical information, please contact Ascent Research.
